KalVista Pharmaceuticals, Ltd. clinical trials

Acquired by Chiesi Farmaceutici S.p.A., Jun 11, 2026 · source ↗

The registry lists 15 studies whose lead sponsor is KalVista Pharmaceuticals, Ltd.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 17, 2026.

Before and after it joined Chiesi Farmaceutici S.p.A.

First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.: 14
First submitted after KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.: 1
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 11
Terminated: 1
Recruiting: 1
Available: 1
Approved for marketing: 1

Phase

Phase 3: 4
Phase 1: 4
Phase 2: 3
Phase 4: 1

Where

United States: 12
United Kingdom: 8
Germany: 6
France: 5
Italy: 5
Canada: 5

Registry sponsor names on this page

KalVista Pharmaceuticals, Ltd.15 studies

Something wrong with this grouping? Tell us on the Chiesi Farmaceutici S.p.A. page.

Studies

Recruiting first, then most recently updated. Showing 15 of 15. All Chiesi Farmaceutici S.p.A. studies →

Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)RecruitingNCT07654829Phase 4
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted after KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With SebetralstatAvailableNCT07216378
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or IICompletedNCT06467084Phase 3
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 TrialCompletedNCT05511922Phase 3
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)CompletedNCT05505916Phase 3
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or IITerminatedNCT05055258Phase 2
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE AttacksCompletedNCT07009262
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With SebetralstatApproved for marketingNCT06628713
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or IICompletedNCT04208412Phase 2
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)CompletedNCT05259917Phase 3
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy VolunteersCompletedNCT04349800Phase 1
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy VolunteersCompletedNCT05178355Phase 1
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) FormulationsCompletedNCT05118958Phase 1
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)CompletedNCT03466099Phase 2
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DMECompletedNCT02193113Phase 1
Sponsor listed in the registry: KalVista Pharmaceuticals, Ltd. · First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A.